Importantly, it had been reported that expressional levels of ICAM1 serve as a predictor of clinical outcome in several types of cancer including metastatic colorectal cancer (63), indolent non-Hodgkin lymphomas (64), high-grade serous ovarian carcinoma (65) and glioblastoma (66). This evidence concerns the gene ICAM1 and cancer.